| Title |
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
|
|---|---|
| Published in |
Neurotherapeutics, January 2013
|
| DOI | 10.1007/s13311-012-0162-5 |
| Pubmed ID | |
| Authors |
Harold L. Atkins, Mark S. Freedman |
| Abstract |
Reports from more than 600 hematopoietic stem cell transplants (HSCT) have appeared in the medical literature for the last 1 and one-half decades. The patient's own stem cells are harvested and stored temporarily while high doses of chemotherapy and biologics are used to destroy the auto-destructive immune system. The immune system is regenerated from the infused autologous hematopoietic stem cells. Increasing clinical experience has refined patient selection criteria and management in the peri-transplant period leading to a reduction in treatment-related complications. HSCT, when used to treat patients with aggressive highly active multiple sclerosis, can reduce or eliminate ongoing clinical relapses, halt further progression, and reduce the burden of disability in some patients, in the absence of chronic treatment with disease-modifying agents. The top 10 lessons learned from the growing experience using HSCT for the treatment of multiple sclerosis are discussed. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 25% |
| United States | 1 | 13% |
| Australia | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| Brazil | 2 | 1% |
| Chile | 1 | <1% |
| Germany | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 136 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 15% |
| Student > Bachelor | 22 | 15% |
| Researcher | 15 | 10% |
| Student > Master | 14 | 10% |
| Other | 12 | 8% |
| Other | 24 | 17% |
| Unknown | 34 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 29% |
| Agricultural and Biological Sciences | 20 | 14% |
| Neuroscience | 14 | 10% |
| Biochemistry, Genetics and Molecular Biology | 6 | 4% |
| Immunology and Microbiology | 3 | 2% |
| Other | 16 | 11% |
| Unknown | 42 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2021.
All research outputs
#926,023
of 25,371,288 outputs
Outputs from Neurotherapeutics
#67
of 1,308 outputs
Outputs of similar age
#7,223
of 288,986 outputs
Outputs of similar age from Neurotherapeutics
#2
of 12 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.